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Abstract: A mixture normal model has been developed to partition genotypes in predicting quantitative phenotypes. Its estimation 
and inference are performed through an EM algorithm. This approach can conduct simultaneous genotype clustering and hypothesis 
testing. It is a valuable method for predicting the distribution of quantitative phenotypes among multi-locus genotypes across genes 
or within a gene. This mixture model’s performance is evaluated in data analyses for two pharmacogenetics studies. In one example, 
thirty five CYP2D6 genotypes were partitioned into three groups to predict pharmacokinetics of a breast cancer drug, Tamoxifen, 
a CYP2D6 substrate (p-value = 0.04). In a second example, seventeen CYP2B6 genotypes were categorized into three clusters to 
predict CYP2B6 protein expression (p-value = 0.002). The biological validities of both partitions are examined using established 
function of CYP2D6 and CYP2B6 alleles. In both examples, we observed genotypes clustered in the same group to have high 
functional similarities. The power and recovery rate of the true partition for the mixture model approach are investigated in statistical 
simulation studies, where it outperforms another published method. 
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Introduction
Genetic association studies have been widely used to 
identify risk factors for complex diseases or to predict 
drug-treatment  outcomes  (efficacy  or  toxicity). 
One  important  approach  is  called  candidate  gene 
approaches.1 It is frequently selected to investigate 
genes in known signaling and metabolic pathways. 
This  approach  typically  narrows  gene  targets  to 
a handful of candidates deemed to have a stronger 
potential of affecting outcomes. Consequently, it is 
feasible to investigate a dense SNP set per gene. For 
example, in our pharmacokinetics study of Tamoxifen 
in breast cancer patients, 35 CYP2D6 alleles were 
investigated  from  more  than  70  known  CYP2D6 
polymorphisms.
In  a  candidate  gene  study,  multiple  SNPs  per 
gene  usually  lead  to  many  haplotypes  or  alleles, 
creating  high  genotype  dimensions  for  genotype/
phenotype association analysis. A striking example 
is  the  CYP2D6  gene,  which  has  greater  than  70 
alleles,  including  mutations,  deletions,  insertions, 
gene  conversions  and  duplications  (www.imm.
ki.se/CYPalleles).
To  have  potential  clinical  benefit,  association 
studies must address a two-fold question: whether 
a  phenotype  is  associated  with  genetic  variations, 
and  whether  the  clinical  outcome  distribution 
among  genotypes  is  well-defined  (i.e.  how  many 
sub-population groups can be predicted by genetic 
polymorphisms).  An  ideal  statistical  approach 
should  have  a  high  power  to  test  genetic  effects 
on the phenotypes. It should also be able to group 
combinations  of  genetic  variables  into  clusters, 
where  samples  in  each  cluster  share  a  similarly 
distributed  phenotype.  Clustered  genotypes  that 
predict phenotypes have high clinical relevance as 
possible  diagnostic  markers,  which  could  directly 
facilitate future clinical decisions.
In  traditional  statistical  theory,  many  multiple 
comparison approaches were developed.2,3 Scheffe, 
LSD, and Tukey’s HSD tests can evaluate the overall 
phenotype  difference  among  genotype  groups,  but 
they can’t tell where the difference is. Newman-Kuels 
and Duncan tests are able to search for phenotype 
differences  sequentially  among  genotype  groups, 
but may result in overlapped grouping [Christensen,2 
page  80,  example  5.5.1].  Therefore,  all  of  these 
approaches are capable of addressing the first part of 
the prescribed two-folded question: whether there is 
any genetic effect on the phenotype. However, none 
of them can provide decisive answer to the second 
part of the question: how genetic polymorphisms are 
grouped to predict the phenotype.
A  restricted  partition  method  (RPM)  has  been 
proposed4 to address these two aims. The algorithm 
ranks the genotype groups from the smallest to the 
largest  according  to  the  phenotype  means.  Then, 
adjacent  genotype  groups  are  merged  sequentially 
based on a Tukey’s HSD test until it reaches a pre-
specified significant level. The overall type I error is 
controlled by the empirical distribution constructed 
for the R2 statistic from a regression of the quantitative 
trait  value  on  the  final  genotype  grouping.  This 
RPM method is an extension of a proposed multiple 
comparison  approach  for  quantitative  phenotypes. 
It  has  two  important  features  that  may  affect  its 
implementation. At first, it has inherent assumptions 
of  equal  phenotypic  variance  and  equal  sample 
sizes  among  genotype  cells  in  Tukey’s  HSD  test. 
In practice, this assumption may or may not hold. 
Secondly,  it  uses  disparate  methods  for  genotype 
grouping (Tukey’s HSD test) and testing genotype/
phenotype  associations  (R2).  Arbitrary  threshold 
selection  for  both  methods  may  not  guarantee  the 
optimal partition.
In  this  paper,  we  propose  a  parametric  mixture 
model  approach  to  genetic  association  studies, 
where  the  quantitative  phenotype  is  assumed  to 
follow multivariate normal distribution. Differential 
genotype cells are allowed to have different means 
and variances. A sequential likelihood ratio test, i.e. 
one mixture vs. two mixtures, two vs. three, and so on, 
among subgroups defined by genetic polymorphisms 
indicates the significance of the genetic effect on the 
phenotype. The optimal partition among genotypes 
for phenotype prediction is determined by probability 
assignments from the mixture model. Therefore, this 
mixture model approach can simultaneously perform 
p-value  calculation  and  determine  the  optimal 
genotype  partition.  The  innovation  of  our  mixture 
model includes an added penalty term to avoid non-
identifiable parameters.
The  performance  of  our  approach  is  evaluated 
with two pharmacogenetics study examples, in which 
CYP2D6  and  CYP2B6  alleles  were  genotyped  to 
predict the pharmacokinetics of a CYP2D6 substrate A Penalized mixture model approach in genotype/phenotype
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and  CYP2B6  protein  expression  respectively. 
Because the functional relationship between CYP2D6 
alleles and metabolic activity and CYP2B6 alleles 
and protein expression has been extensively studied, 
their function based partitions will serve as objective 
standards  for  assessing  our  mixture-model-based 
partitions.  In  addition,  statistical  simulations  were 
conducted to compare performance of RPM and the 
mixture model.
Methods
Mixture model specification
The  history  of  the  mixture  model’s  application  in 
genetics can be traced back as far as 1800s.5 Many 
important contributions of this approach in population 
genetics are well documented.6 We emphasize that 
the traditional mixture model approach has been to 
infer whether a phenotype from the population (such 
as blood pressure or drug response) is composed of 
multiple  sub-populations  determined  by  possible 
underlying,  unknown  genotypes.  The  mixture 
model  formulation  and  its  estimation  procedure 
are  introduced  in  great  detail  by  McLachlan.7 
We reformulate  the  traditional  mixture  model  to 
estimate if measured genotype groups can predict a 
number of unknown, underlying normal mixtures in 
measure phenotypes.
Let us assume that we have G genotype groups, 
and  every  genotype  group  has  ng  (g  =  1, …, G) 
phenotype  samples,  yg = (          yg1, …, ygng),  where  ygi  is 
a normal random variable. We write the probability 
of the measured phenotype y as a function of the 
observed G genotype groups defining partitions of y 
and the assignment of phenotype group yg to one of 
the assumed K clusters
  Pr( , | , )
Pr | ,
{ }
,..., ,...,
y z
y
µ µ σ σ
2
2
1 1
= ( ) 


 ∏
=
= =
g k k k
I z k
k K g G
p
g
m s ∏ ∏
( )
= ( )
- ∑ 



=
,
Pr | ,
exp
( ) ,...,
yg k k
k
n
gi k i n
k
i
g y
m
πs
m
s
s
2
2 2
2
1
2 2
2
 



 
(1) 
 
where  zg = 1,  2, …, K  is  a  multi-nominal  random 
variable,  and  I{zg = k}  indicates  genotype  group  g   
follows  distribution  Pr(yg | mk,  sk).  For  the  sake  of 
simplicity, let’s define sgk = I{zg = k}. The log-likelihood 
for mixture model (1) is
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Under the null hypothesis, the true model has only 
one distribution. If we fit the data by a mixture of 
K-components,  any  (   pk = p0  =  ptrue,  0    pk  1, 
k = 1, …, K   )  will  achieve  the  maximum  in  (2). 
This problem causes not only numerical difficulties 
in the mixture model estimation process,8 but also 
theoretical difficulties in likelihood ratio tests.9,10 
The  identification  problem  was  solved  in11  by 
adding  a  penalty  term  into  the  log-likelihood 
function  (2),  by  which  the  penalized  likelihood 
function pl(.), (3), forces pk = 1/K when it reaches 
the maximum.
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Our aim is the classification of the genotype cells, 
while Chen11 classify individual observations. This 
difference leads to distinctive estimation algorithms 
and asymptotic LRT.
e-M algorithm
In the estimation step (E-step), the random variable 
zgk (un-observed) is estimated by (4):
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The grouping of genotype g is based on the its 
highest probability assignment,
  group(g) = aug maxk = 1, …, K{sgk}  (5)
In the maximization step (M-step),
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The E- and M-steps are iteratively conducted, and 
the convergence is monitored based on the relative 
difference of the penalized likelihood function (3).
sequential log-likelihood ratio test
To test the number of normal distribution mixtures 
present in the observed genotypes, a likelihood ratio 
test (LRT) is conducted. The marginal penalized log-
likelihood for a mixture model of K-component is 
listed in (7).
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The LRT is calculated by
	 λ	= -2[      plM (Kl) - plM (K2)]. 
This LRT will be conducted sequentially in data 
analysis, i.e. (K1, K2) = (1, 2), (2, 3), (3, 4), etc., for 
all (K1, K2) with K2  g. The family-wise type I error 
is  calculated  as  the  cumulative  p-value  along  the 
sequential test. The threshold is pre-specified at the 
5% level. For each LRT step, parametric bootstrap 
(5,000 replications) is implemented to calculate the 
empirical p-value.
Data Analysis
Pharmacogenetic study of CYP2D6 
genetic effect on tamoxifen metabolites 
in patients with breast cancer
N-Desmethyltamoxifen  (NDM),  a  major  primary 
metabolite of tamoxifen, is hydroxylated by CYP2D6 
to yield endoxifen. Due to its high antiestrogenic 
potency, endoxifen may play an important role in 
the  clinical  activity  of  tamoxifen.  We  conducted 
a  prospective  trial  in  158  breast  cancer  patients 
taking  tamoxifen  to  further  understand  the  effect 
of CYP2D6 genotype and concomitant medications 
on  endoxifen  plasma  concentrations.  Thirty-five 
different  genotypes  (Fig.  1a)  were  determined 
from  the  17  CYP2D6  alleles  assayed.  Plasma 
concentrations  of  tamoxifen  and  its  metabolites 
were determined at the fourth month of tamoxifen 
treatment.
The  NDM/Endoxifen  ratio  data  were  log-
transformed  for  better  normal  mixture  model 
fitting.  However,  the  sample  size  and  variance 
are  clearly  unequally  distributed  among  35 
genotype  cells  (Fig. 1a).  Applying  the  mixture 
model,  the  sequential  LRTs  (Table  1)  suggest 
the 35 genotype cells were optimally partitioned 
into  three  groups.  Sequential  test  p-values  for 
testing  mixtures  (1  vs.  2),  (2  vs.  3),  (3  vs.  4) 
were 0.008, 0.032, and 0.143 respectively, with 
a  cumulative  p-value = 0.040  for  the  mixture 
model  of  3  components.  The  genotype  group 
with  smallest  log(NDM/Endoxifen)  contains 
genotypes *3/*41, *17/*41, *4/*4, and *41/*41 
(group 1 in Table 1). It has a mean of -3.76 and a 
SD = 0.15, and approximately 12% of the samples 
belong to this group. The second genotype group 
contains  *4/*41,  *10/*4,  *10/*4xn,  *35/*41, 
*1/*10,  *10/*2,  *35/*5,  *10/*41,  *2/*4,  *1/*3, 
*2/*41xn, *2/*35, *1/*4, *5/*9, *1/*41, *1/*29, 
*1/*35,  *35/*4,  *1/*5,  *2/*41,  and  *41/*9.  Its 
log(NDM/Endoxifen) has a mean of -2.82 and a 
SD = 0.40, and 50% of the samples belong to this 
group. The third group contains genotypes *1/*2, 
*2/*2, *1/*1, *2/*9, *10/*35, *1/*1xn, *2xn/*4, 
*1xn/*2, *41/*41xn, and *1/*2xn. It has the largest 
log(NDM/Endoxifen)  with  a  mean  –2.28  and  a 
SD = 0.42, and 38% of the samples belong to this 
group. Figure 1b displays the three mixture density 
distributions.  Figure  1c  shows  genotype  cell 
probability assignments (sgk) to each of the three 
predicted  normal  mixture  components,  where 
colored bar lengths (scaled on (0,1)) indicate the 
value of sgk for each mixture component.
RPM was conducted for the log(NDM/Endoxifen) 
data.  Results  are  presented  in  Table  2.  The  RPM 
sequential  analysis  stopped  at  the  first  iteration, 
with  p-value = 0.036.  The  result  suggests A Penalized mixture model approach in genotype/phenotype
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log(NDM/Endoxifen) is significantly different among 
all 35 genotype cells.
Pharmacogenetic study of CYP2B6 
genetic effect on its protein  
expression in human liver tissues
We conducted a retrospective study, investigating the 
effect CYP2B6 genetic polymorphisms on CYP2B6 
protein  expression  in  83  human  liver  tissues. 
Seventeen genotypes (Fig. 2a) were determined from 
9 CYP2B6 alleles assayed (*1, *2, *4, *5, *6, *13, 
*14, *15, and *22). This data were recently published 
by our group.12 Protein expression level was done with 
western blotting in liver microsome samples. Much 
detail method description was described in13 CYP2B6 
protein expression data was fitted using the normal 
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Figure 1. genotype/phenotype association analysis for the Tamoxifen study. A) is a raw data description. The x-axis is the nDM/endoxifen ratio in 
log-scale, where both nDM and endoxifen are Tamoxifen metabolites. The y-axis denotes the 35 CYP2D6 genotypes. B) Thirty-five genotypes are 
clustered into three groups by a mixture model, which are characterized by three normal distributions. The x-axis is the nDM/endoxifen ratio in log-scale, 
and y-axis is the probability density. c) shows genotype cell probability assignments (sgk) to each of the three predicted normal mixture components, 
where colored bar lengths (scaled on (0,1)) indicate the value of sgk for each mixture component. In A), B), and c), green, blue, and red colors represent 
the memberships of three clusters.Li et al
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mixture model. Sample size and variance were clearly 
unequally distributed among 17 genotypes (Fig. 2a). 
The  sequential  LRT  (Table  1)  suggests  CYP2B6 
protein expression levels are optimally portioned into 
three groups based on genotype. The sequential test 
p-values for testing mixtures (1 vs. 2), (2 vs. 3), (3 vs. 4) 
were  0.001,  0.001,  and  0.153  respectively,  with  a 
cumulative p-value = 0.002 for the mixture model of 3 
components. The genotype group with smallest mean 
protein expression contains genotypes *6/*13, *5/*5, 
*5/*6, *1/*15, *5/*15, and *1/*4 (group 1 in Table 1). 
It has a mean of 2.81(pmol/mg) and a SD = 1.64, and 
approximately 31% of samples belong to this group. 
The second genotype group contains *6/*14, *2/*4, 
*1/*5, *6/*6, *1/*6, *5/*22, *2/*22, *4/*6 and *1/*2. 
Its protein expression has a mean of 11.6(pmol/mg) 
and a SD = 58.1, and 52% of the samples belong to 
this group. The third group contains genotypes *1/*22 
and *1/*1. It has the largest protein expression with 
mean 28.1(pmol/mg) and SD = 259.7, and 17% of the 
samples belong to this group. Figure 2b displays the 
three mixture density distributions. Figure 2c shows 
genotype cell probability assignments (sgk) to each of 
the three predicted normal mixture components.
RPM  was  conducted  for  the  CYP2B6  protein 
expression data. Results are presented in Table 2. The 
RPM sequential analysis stopped at the first iteration, 
with  p-value = 0.007.  The  result  suggests  mean 
protein expression is significantly different among all 
17 genotypes.
simulation studies
The  preceding  data  analyses  show  discrepancies 
between the mixture model and RPM approaches. 
In these comparisons, RPM partitions the genotype 
cells into more subgroups than the mixture model. 
As  both  methods  emphasize  the  importance  of 
dimensionality  reduction,  we  look  favorably  on 
the  mixture  model  result,  though  both  detected 
significant genotype/phenotype associations in their 
respective  genotype  partitions.  In  the  following 
simulation studies under two epistatic models, we 
compare the power of the two approaches to detect 
genetic  effects  and  model  recovery  probabilities. 
Of importance is the ability of both approaches to 
recover the true model partition.
Data were simulated from two 2-locus, bi-allelic 
models:  a  checkerboard  model  (Fig.  3a)  and  a 
diagonal  model  (Fig.  3b). These  two  models  have 
been  thoroughly  described  by  Culverhouse.14  For 
each model, both alleles at each of the contributing 
loci are equally frequent (minor allele frequencies for 
a and b are 0.5), and the phenotype in each genotype 
cell is normally distributed.
Checkerboard  models  were  simulated  with 
2  distributions  among  the  9  cells,  with  equal  or 
unequal variances. One group consists of 4 genotype 
cells containing exactly one heterozygote (Fig. 3a, 
shaded cells), with a phenotypic mean of 0. The other 
five genotype cells have a higher phenotypic mean. 
Table 1. Mixture model based data analyses.
phenotypes Group ID Mixture Dist. and 
prob. n(µ, σ  2; p)
Genotype grouping
Tamoxifen study 1 n(-3.76, 0.15; 0.12) *3/*41, *17/*41, *4/*4, *41/*41
Log 
(nDM/endoxifen)
2 n(-2.82, 0.40; 0.50) *4/*41, *10/*4, *10/*4xn, *35/*41, *1/*10, *10/*2, *35/*5, 
*10/*41, *2/*4, *1/*3, *2/*41xn, *2/*35, *1/*4, *5/*9, 
*1/*41, *1/*29, *1/*35, *35/*4, *1/*5, *2/*41, *41/*9
3 n(-2.28, 0.42; 0.38) *1/*2, *2/*2, *1/*1, *2/*9 *10/*35, *1/*1xn, *2xn/*4,  
*1xn/*2, *41/*41xn, *1/*2xn
efavirenz study 1 n(2.81, 1.64; 0.31) *6/*13, *5/*5, *5/*6, *1/*15, *5/*15, *1/*4
Protein expression 
(pmol/mg)
2 n(11.6, 58.1; 0.52) *6/*14, *2/*4, *1/*5, *6/*6, *1/*6, *5/*22, *4/*6, *2/*22, 
*1/*2
  3 n(28.1, 259.7; 0.17) *1/*22, *1/*1
Table 2. rPM based data analyses.
  Tamoxifen study cYp2B6 study
P-value 0.036 0.007
grouping 35 groups for  
35 genotypes
17 groups for 
17 genotypesA Penalized mixture model approach in genotype/phenotype
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Diagonal models were simulated with 3 distributions 
among the 9 cells, with equal or unequal variances. 
All the cells off the main diagonal have a phenotypic 
mean of 0. The diagonal cells (Fig. 3a, dark shaded 
cells) have higher phenotypic means, with the double 
heterozygote (Fig. 3a, light shaded cell) phenotypic 
mean as half that of the other two cells, but with equal 
variance.
The  data  were  simulated  as  follows:  assuming 
unrelated individuals, genotype cells are simulated 
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Figure 2. genotype/phenotype association analysis for the CYP2B6 study. A) is a raw data description. The x-axis is the CYP2B6 protein expression 
(pmol/mg). The y-axis denotes the 17 CYP2B6 genotypes. B) seventeen genotypes are clustered into three groups by a mixture model, which are 
characterized by three normal distributions. The x-axis is the protein expression level, and y-axis is the probability density. c) shows genotype cell 
probability assignments (sgk) to each of the three predicted normal mixture components, where colored bar lengths (scaled on (0,1)) indicate the value of 
sgk for each mixture component. In A), B), and c), green, blue, and red colors represent the memberships of three clusters.Li et al
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independently  based  on  allele  frequencies.  Given 
an  individual  genotype  cell,  the  phenotype  was 
generated from a normal distribution. Phenotypes were 
simulated under two variance assumptions. In situation 1 
(equal variance), one group of cells follows N(1, 12), and 
the other group follows N(1 + m, 12), where m = 0.25, 
0.5,  and  1.  In  situation  2  (unequal  variance),  one 
group of cells follows N(1, 12), and the other group 
follows N(1 + m, 22), where m = 0.25, 0.5, and 1. 1000 
datasets were simulated, each containing 500 samples. 
In situation 3 (Gamma Distribution), one group of 
cells follows a gamma distribution of mean = 1 and 
variance = 1, and the other group follows a gamma 
distribution of mean = 1 + m, and variance = 1, where 
m = 0.25, 0.5, and 1.
In  both  RPM  and  mixture  model  analysis,  the 
p-value threshold is set at 0.1% level in order to make 
the  simulation  results  comparable  to  the  original 
PRM simulation studies.4 Power and model recovery 
probabilities  from  the  simulations  are  reported  in 
Table 3. Power was calculated by the proportion of 
simulated data sets where the null hypothesis was 
rejected. Recovery probability was estimated by the 
proportion of simulated data sets in which the true 
partition was recovered. Highlights of simulation are 
summarized as following:
•  For models with equal variance among genotype 
cells  (situation  1),  both  RPM  and  the  mixture 
model methods demonstrated comparable power, 
but the mixture model had much higher recovery 
probabilities.
•  For models with unequal variance among genotype 
cells  (situation  2),  the  mixture  model  approach 
was  more  powerful  and  had  higher  recovery 
probabilities than RPM.
•  For  RPM  in  the  unequal  variance  situation, 
both  checkerboard  and  diagonal  models  had 
considerable  discrepancies  between  power  and 
recovery probability estimates. This result is due 
to early rejection of the RPM multiple comparison 
tests, making it unable to fully recover the true 
partition.
•  Comparing  the  simulations  under  equal  and 
unequal variance, the mixture model gained power 
and had increased partition recovery probability 
for models of unequal variance.
•  If  the  data  distribution  is  un-symmetric  (i.e. 
gamma  distribution),  both  mixture  model  and 
RPM  methods  have  comparable  performance 
comparing  their  performance  in  data  following 
normal distribution, respectively.
Discussion and conclusion
The penalized mixture model approach for quantitative 
phenotypes  is  a  novel  application  of  the  mixture 
model to genotype clustering in genetic association 
studies. As demonstrated in pharmacogenetic studies 
of CYP2D6 and CYP2B6, along with simulations, this 
mixture model method is capable of clustering local 
haplotypes and multi-locus genotypes to significantly 
reduce  complexity  of  high-dimensional  genotype 
space. The approach has power to detect quantitative 
traits loci when genetic effects on phenotypes are 
marginal or purely epistatic. As demonstrated in two 
pharmacogenetic  genetic  studies  and  simulations, 
it can detect both main and interactions effects of 
genetic polymorphisms on quantitative phenotypes.
Investigating the effect of CYP2D6 genotype on 
CYP2D6  metabolism  of  N-Desmethyltamoxifen, 
the  mixture  model  approach  generated  three 
CYP2D6 genotype clusters in predicting log(NDM/
Endoxifen).  Before  we  discuss  the  biological 
rational  for  this  classification,  let  us  review  the 
functionality of CYP2D6 alleles. CYP2D6*1 is the 
wild type allele, which codes for a fully functional 
enzyme. CYP2D6*2, *33 and *35 alleles contain 
point  mutations  that  do  not  affect  the  catalytic 
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Figure  3.  Bi-allelic  epistatic  models.  A)  Checkerboard  model  was 
simulated with 2 distributions among the 9 cells, with equal or unequal 
variances. One group consists of 4 genotype cells containing exactly one 
heterozygote (shaded cells), with a phenotypic mean of 0. The other five 
genotype cells have a higher phenotypic mean. B) Diagonal model was 
simulated with 3 distributions among the 9 cells, with equal or unequal 
variances. All the cells off the main diagonal have a phenotypic mean 
of  0.  The  diagonal  cells  (dark  shaded  cells)  have  higher  phenotypic 
means, with the double heterozygote (light shaded cell) phenotypic mean 
as half that of the other two cells, but with equal variance.A Penalized mixture model approach in genotype/phenotype
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Table 3. simulation studies.
µ RpM Mixture model
power Recovery- 
probability
power Recovery-  
probability
situation 1: equal variance
Check board model
0.25 8% 9.7% 8.6% 49.8%
0.50 87% 51.4% 88.5% 83.2%
1.00 100% 79.3% 100% 99.8%
Diagonal model
0.25 40% 1.3% 44.3% 33.2%
0.50 100% 44.3% 100% 61.1%
1.00 100% 86.5% 100% 97.9%
situation 2: Unequal variance
Checkerboard model
0.25 0.4% 5.8% 13.5% 77.8%
0.50 16.4% 22.4% 92.9% 92.3%
1.00 99.8% 0.3% 100% 100%
Diagonal model
0.25 0.6% 0.2% 54.4% 49.4%
0.50 15.2% 0.2% 100% 82.3%
1.00 95.4% 0.2% 100% 100%
situation 3: skewness  
(gamma distribution)
Check board model
0.25 7.5% 5.5% 7.3% 49.3%
0.50 82% 46.3% 85.5% 84.2%
1.00 99% 74.3% 98.3% 93.8%
Diagonal model
0.25 38% 2.3% 39.3% 36.7%
0.50 100% 43.4% 100% 63.2%
1.00 100% 87.4% 100% 98.9%
properties  of  the  protein  product.  CYP2D6*3–8, 
*11–16, *18–20, *38, *40, *42, *44 are associated 
with no enzymatic activity and CYP2D6*9, *10, 
*17, *29, *36, *37, *41 with reduced activity.15–17 
The presence of multiple copies of CYP2D6 alleles 
(i.e.  *1,  *2,  *35,  *41)  have  been  reported  in 
subjects  with  unusually  high  CYP2D6  catalytic 
activity.18,19
Based on this prior functional information, all of 
the CYP2D6 alleles contained in the first genotype 
group in Table 1 have either no or reduced enzymatic 
activity. The majority of alleles in the third genotype 
group have either normal or high activities. There 
are only four heterozygous diplotypes that possess 
low  enzymatic  activity:  *2/*9,  *10/*35,  *2xn/*4 
and  *41/*41xn. With  the  exception  of  *2/*35  and 
*1/*35,  almost  no  genotypes  in  the  middle  group 
are homozygous for normal or no-enzymatic activity 
alleles. If these six genotype groups (*2/*9, *10/*35, 
*2xn/*4, *2/*35, *1/*35) were misclassified by the 
mixture model, they are account for only 10 out of 
158  samples  (6%).  Therefore,  the  mixture  model 
based partition is accurate according to well defined 
functionality of CYP2D6 alleles.Li et al
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In  exploring  the  effect  of  CYP2B6  genotype 
on  expression  of  its  protein  product,  9  alleles 
were  genotyped.  CYP2B6  *1  represents  fully 
functional  expression  and  activity  while  *22  is 
associated with increased CYP2B6 expression.20 The 
*5 allele reduces CYP2B6 protein by about 8-fold in 
isolated human liver microsomes.13 The *6 allele has 
been shown to reduce function in vitro as well as the 
pharmacokinetics of its substrate efavirenz in clinical 
studies.21,22  The  other  alleles  (*2,  *13,  *14,  *15) 
have very low or completely absent function.13,23,24 
CYP2B6*4  appears  to  increase25  or  decrease  (our 
data) activity depending on the substrate tested.
Three CYP2B6 genotype clusters generated from 
the mixture model reasonably reflect our expectation 
based on these prior studies. Genotypes in the cluster 
with the highest protein level are composed of only 
fully functional alleles, *1 and *22. Most genotypes 
in the lowest protein level cluster are composed of 
two  low  or  non-functional  alleles  (*2,  *4,  *5,  *6, 
*13, *15), with the exception of *1/*15 and *1/*4. 
Most of genotypes in the middle cluster contain one 
functional allele and one low or non-functional allele, 
apart from *4/*6, *6/*14, *2/*4, and *6/*6. If these 
six genotype groups (*1/*15, *1/*4, *6/*14, *2/*4, 
*6/*6,  *4/*6)  were  misclassified  by  the  mixture 
model, they account for 12 out of 83 samples (14.4%). 
In both examples, mixture model based partitions on 
CYP2D6 and CYP2B6 genotypes are supported by 
their functional information.
Comparing RPM to the mixture model approach, 
RPM detected genotype/phenotype associations with 
similar power. However, in the CYP2D6 and CYP2B6 
pharmacogenetic studies, the mixture model generates 
three clusters for each data set, while RPM generated as 
many clusters as the original genotype cells. The result 
suggests a tendency of over clustering by the RPM 
method. This characteristic of RPM is confirmed in 
the simulation study, where RPM had a lower recovery 
rate for the true partition compared with the mixture 
model approach. Improvement in the mixture model’s 
recovery rate was observed when the assumption of 
equal  variance  among  groups  was  violated,  while 
RPM’s recovery probability was diminished.
In  summary,  the  mixture  model  approach  has 
adequate power to detect genetic effects on phenotypes 
and simultaneously cluster multiple genetic variables 
into homogeneous phenotype groups.
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